| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiparasitics, ivermectin derivatives | 3972 | 70288-86-7 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form. In vitro data suggest evidence of activity against SARS-CoV-2, but to date available data are insufficient to recommend either for or against the use of ivermectin for the treatment of COVID-19. FDA issued a warning concerning possi-ble inappropriate use of ivermectin products intended for animals as an attempt to self-medicate for the treat-ment of COVID-19.
|
| Dose | Unit | Route |
|---|---|---|
| 12 | mg | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 4 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.17 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 22, 1996 | FDA | MERCK SHARP DOHME |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 274.76 | 28.77 | 60 | 3750 | 2984 | 50598330 |
| Ocular hyperaemia | 180.85 | 28.77 | 65 | 3745 | 20227 | 50581087 |
| Asthenia | 162.22 | 28.77 | 156 | 3654 | 318886 | 50282428 |
| Headache | 149.81 | 28.77 | 186 | 3624 | 506349 | 50094965 |
| Vertigo | 139.48 | 28.77 | 71 | 3739 | 51761 | 50549553 |
| Malaria | 108.56 | 28.77 | 18 | 3792 | 194 | 50601120 |
| Skin irritation | 81.15 | 28.77 | 28 | 3782 | 7699 | 50593615 |
| Somatic delusion | 78.93 | 28.77 | 16 | 3794 | 550 | 50600764 |
| Coma | 74.98 | 28.77 | 49 | 3761 | 56830 | 50544484 |
| Pyrexia | 73.14 | 28.77 | 114 | 3696 | 380089 | 50221225 |
| Logorrhoea | 56.46 | 28.77 | 16 | 3794 | 2308 | 50599006 |
| Encephalopathy | 54.31 | 28.77 | 33 | 3777 | 33678 | 50567636 |
| Skin burning sensation | 49.33 | 28.77 | 21 | 3789 | 10164 | 50591150 |
| Depressed level of consciousness | 47.95 | 28.77 | 36 | 3774 | 51917 | 50549397 |
| Abnormal faeces | 47.15 | 28.77 | 16 | 3794 | 4180 | 50597134 |
| Erythema | 46.31 | 28.77 | 56 | 3754 | 146358 | 50454956 |
| Gastrointestinal motility disorder | 46.02 | 28.77 | 16 | 3794 | 4493 | 50596821 |
| Urine odour abnormal | 43.28 | 28.77 | 16 | 3794 | 5357 | 50595957 |
| Oral discomfort | 40.39 | 28.77 | 17 | 3793 | 8000 | 50593314 |
| Pruritus | 35.99 | 28.77 | 71 | 3739 | 283497 | 50317817 |
| Dermatitis contact | 35.91 | 28.77 | 16 | 3794 | 8630 | 50592684 |
| Urinary incontinence | 31.61 | 28.77 | 22 | 3788 | 28186 | 50573128 |
| Product use in unapproved indication | 31.32 | 28.77 | 41 | 3769 | 115778 | 50485536 |
| Rash papular | 30.18 | 28.77 | 16 | 3794 | 12588 | 50588726 |
| Language disorder | 28.97 | 28.77 | 9 | 3801 | 1779 | 50599535 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 885.46 | 36.32 | 179 | 5151 | 2469 | 29566728 |
| Ocular hyperaemia | 646.24 | 36.32 | 175 | 5155 | 8952 | 29560245 |
| Asthenia | 495.37 | 36.32 | 362 | 4968 | 214888 | 29354309 |
| Headache | 474.60 | 36.32 | 325 | 5005 | 173682 | 29395515 |
| Coma | 401.85 | 36.32 | 177 | 5153 | 39273 | 29529924 |
| Vertigo | 305.53 | 36.32 | 123 | 5207 | 21738 | 29547459 |
| Pyrexia | 271.93 | 36.32 | 293 | 5037 | 287329 | 29281868 |
| Urinary incontinence | 248.46 | 36.32 | 98 | 5232 | 16383 | 29552814 |
| Malaria | 227.64 | 36.32 | 38 | 5292 | 157 | 29569040 |
| Back pain | 169.86 | 36.32 | 143 | 5187 | 102141 | 29467056 |
| Encephalopathy | 155.20 | 36.32 | 86 | 5244 | 30957 | 29538240 |
| Gait disturbance | 150.16 | 36.32 | 116 | 5214 | 73233 | 29495964 |
| Depressed level of consciousness | 104.10 | 36.32 | 71 | 5259 | 36871 | 29532326 |
| Abnormal behaviour | 86.16 | 36.32 | 53 | 5277 | 23074 | 29546123 |
| Language disorder | 81.91 | 36.32 | 25 | 5305 | 1934 | 29567263 |
| Myalgia | 71.71 | 36.32 | 77 | 5253 | 73942 | 29495255 |
| Arthralgia | 63.68 | 36.32 | 100 | 5230 | 139517 | 29429680 |
| Nuchal rigidity | 63.24 | 36.32 | 15 | 5315 | 440 | 29568757 |
| Logorrhoea | 61.99 | 36.32 | 21 | 5309 | 2267 | 29566930 |
| Pruritus | 57.89 | 36.32 | 87 | 5243 | 116762 | 29452435 |
| Adverse event | 56.81 | 36.32 | 35 | 5295 | 15256 | 29553941 |
| Anal incontinence | 55.39 | 36.32 | 26 | 5304 | 6589 | 29562608 |
| Filariasis | 53.36 | 36.32 | 7 | 5323 | 0 | 29569197 |
| Stupor | 47.23 | 36.32 | 18 | 5312 | 2726 | 29566471 |
| Blood smear test abnormal | 45.73 | 36.32 | 6 | 5324 | 0 | 29569197 |
| Chills | 45.52 | 36.32 | 60 | 5270 | 71240 | 29497957 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 1129.30 | 27.78 | 233 | 8556 | 4788 | 64485155 |
| Ocular hyperaemia | 768.45 | 27.78 | 230 | 8559 | 22334 | 64467609 |
| Asthenia | 652.78 | 27.78 | 504 | 8285 | 427540 | 64062403 |
| Headache | 517.31 | 27.78 | 483 | 8306 | 528984 | 63960959 |
| Coma | 441.35 | 27.78 | 222 | 8567 | 87393 | 64402550 |
| Vertigo | 404.96 | 27.78 | 185 | 8604 | 58826 | 64431117 |
| Malaria | 336.19 | 27.78 | 56 | 8733 | 319 | 64489624 |
| Pyrexia | 335.72 | 27.78 | 394 | 8395 | 558250 | 63931693 |
| Urinary incontinence | 259.26 | 27.78 | 117 | 8672 | 36034 | 64453909 |
| Encephalopathy | 208.05 | 27.78 | 118 | 8671 | 58701 | 64431242 |
| Back pain | 151.48 | 27.78 | 178 | 8611 | 249993 | 64239950 |
| Depressed level of consciousness | 142.57 | 27.78 | 105 | 8684 | 81331 | 64408612 |
| Gait disturbance | 139.76 | 27.78 | 143 | 8646 | 172012 | 64317931 |
| Abnormal behaviour | 125.68 | 27.78 | 70 | 8719 | 33552 | 64456391 |
| Language disorder | 120.11 | 27.78 | 34 | 8755 | 2683 | 64487260 |
| Logorrhoea | 114.95 | 27.78 | 36 | 8753 | 4023 | 64485920 |
| Pruritus | 78.37 | 27.78 | 147 | 8642 | 312253 | 64177690 |
| Myalgia | 73.61 | 27.78 | 99 | 8690 | 158518 | 64331425 |
| Somatic delusion | 71.47 | 27.78 | 17 | 8772 | 673 | 64489270 |
| Nuchal rigidity | 70.88 | 27.78 | 18 | 8771 | 937 | 64489006 |
| Anal incontinence | 60.49 | 27.78 | 33 | 8756 | 15163 | 64474780 |
| Filariasis | 55.31 | 27.78 | 7 | 8782 | 0 | 64489943 |
| Agitation | 53.44 | 27.78 | 63 | 8726 | 88304 | 64401639 |
| Adverse event | 51.83 | 27.78 | 43 | 8746 | 39446 | 64450497 |
| Stupor | 51.15 | 27.78 | 22 | 8767 | 6013 | 64483930 |
| Chills | 50.86 | 27.78 | 77 | 8712 | 137187 | 64352756 |
| Strongyloidiasis | 50.04 | 27.78 | 18 | 8771 | 3072 | 64486871 |
| Eosinophilia | 44.92 | 27.78 | 39 | 8750 | 38037 | 64451906 |
| Aphasia | 44.47 | 27.78 | 40 | 8749 | 40866 | 64449077 |
| Product use in unapproved indication | 44.02 | 27.78 | 83 | 8706 | 176535 | 64313408 |
| Rhinocerebral mucormycosis | 40.18 | 27.78 | 10 | 8779 | 479 | 64489464 |
| Dysstasia | 38.46 | 27.78 | 29 | 8760 | 23186 | 64466757 |
| Decubitus ulcer | 37.15 | 27.78 | 23 | 8766 | 13356 | 64476587 |
| Speech disorder | 36.94 | 27.78 | 39 | 8750 | 48402 | 64441541 |
| Blood smear test abnormal | 36.50 | 27.78 | 6 | 8783 | 31 | 64489912 |
| Urine odour abnormal | 34.79 | 27.78 | 16 | 8773 | 5120 | 64484823 |
| Gastrointestinal motility disorder | 34.66 | 27.78 | 16 | 8773 | 5163 | 64484780 |
| Skin burning sensation | 34.05 | 27.78 | 20 | 8769 | 10563 | 64479380 |
| Skin irritation | 33.93 | 27.78 | 19 | 8770 | 9175 | 64480768 |
| Diarrhoea | 33.83 | 27.78 | 190 | 8599 | 722514 | 63767429 |
| Abnormal faeces | 32.78 | 27.78 | 16 | 8773 | 5843 | 64484100 |
| Fall | 31.35 | 27.78 | 9 | 8780 | 416817 | 64073126 |
| Arthralgia | 31.27 | 27.78 | 131 | 8658 | 442129 | 64047814 |
| Loss of consciousness | 31.24 | 27.78 | 65 | 8724 | 148300 | 64341643 |
| Oral discomfort | 30.02 | 27.78 | 17 | 8772 | 8389 | 64481554 |
| Fatigue | 28.78 | 27.78 | 36 | 8753 | 748694 | 63741249 |
| Neck pain | 27.86 | 27.78 | 38 | 8751 | 61495 | 64428448 |
None
| Source | Code | Description |
|---|---|---|
| ATC | D11AX22 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
| ATC | P02CF01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Avermectines |
| FDA EPC | N0000175484 | Antiparasitic |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D007306 | Insecticides |
| MeSH PA | D010575 | Pesticides |
| CHEBI has role | CHEBI:24852 | insecticides |
| CHEBI has role | CHEBI:35443 | anthelmintics |
| CHEBI has role | CHEBI:35444 | antinematodal drugs |
| CHEBI has role | CHEBI:35820 | antiprotozoal drugs |
| CHEBI has role | CHEBI:73333 | scabicides |
| FDA EPC | N0000181811 | Pediculicide |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection by Strongyloides | indication | 1214006 | DOID:10955 |
| Infection by Onchocerca volvulus | indication | 38539003 | DOID:11678 |
| Infection by Loa loa | contraindication | 44250009 | DOID:13523 |
| Liver function tests abnormal | contraindication | 166603001 |
| Species | Use | Relation |
|---|---|---|
| Bison | Treatment and control of grubs, Hypoderma bovis | Indication |
| Cats | Prevents heartworm disease | Indication |
| Cats | Removal and control of adult and immature (L4) hookworms, Ancylostoma tubaeforme | Indication |
| Cats | Removal and control of adult and immature (L4) hookworms, A braziliense | Indication |
| Cats | Treatment of adult ear mite (Otodectes cynotis) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Haemonchus placei (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Ostertagia ostertagi (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, O lyrata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Trichostrongylus axei (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, T colubriformis (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Cooperia oncophora (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, C punctata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, C pectinata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Oesophagostomum radiatum (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Nematodirus helvetianus (adults) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, N spathiger (adults) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Bunostomum phlebotomum (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of lungworms, Dictyocaulus viviparus, (adult and L4) | Indication |
| Cattle | Treatment and control of grubs, Hypoderma bovis | Indication |
| Cattle | Treatment and control of grubs, H lineatum | Indication |
| Cattle | Treatment and control of sucking lice, Linognathus vituli | Indication |
| Cattle | Treatment and control of sucking lice Haematopinus eurysternus | Indication |
| Cattle | Treatment and control of sucking lice, Solenopotes capillatus | Indication |
| Cattle | Treatment and control of mites, Psoroptes ovis | Indication |
| Cattle | Treatment and control of mites, Sarcoptes scabiei var bovis | Indication |
| Cattle | Protection (28 days) from reinfection with D viviparus | Indication |
| Cattle | Protection (28 days) from reinfection with O radiatum | Indication |
| Cattle | Protection (21 days) from reinfection with O ostertagi | Indication |
| Cattle | Protection (21 days) from reinfection with T axei | Indication |
| Cattle | Protection (21 days) from reinfection with C punctata | Indication |
| Cattle | Protection (14 days) from reinfection with H placei | Indication |
| Cattle | Protection (14 days) from reinfection with C oncophora | Indication |
| Cervidae | Treatment and control of warbles, Oedemagena tarandi | Indication |
| Dogs | Prevention of heartworm disease | Indication |
| Foxes | Ear mite (Otodectes cynotis) infestations | Indication |
| Horses | Treatment and control of large strongyles, Strongylus vulgaris (adults) | Indication |
| Horses | Treatment and control of large strongyles, S edentatus (adults) | Indication |
| Horses | Treatment and control of large strongyles, S equinus | Indication |
| Horses | Treatment and control of large strongyles, Triodontophorus spp (adults) | Indication |
| Horses | Treatment and control of large strongyles, Craterostomum acuticaudatum (adults) | Indication |
| Horses | Treatment and control of small strongyles, Coronocyclus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cyathostomum spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicocyclus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicodontophorus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicostephanus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Petrovinema poculatum (adults) | Indication |
| Horses | Indication | |
| Horses | Treatment and control of small strongyles, (fourth-stage larvae) | Indication |
| Horses | Treatment and control of pinworms Oxyuris equi (adults and fourth stage larvae) | Indication |
| Horses | Treatment and control of ascarids (adults and third- and fourth-stage larvae) Parascaris equorum | Indication |
| Horses | Treatment and control of Hairworms, Trichostrongylus axei (adults) | Indication |
| Horses | Treatment and control of Large mouth Stomach Worms, Habronema muscae (adults) | Indication |
| Horses | Treatment and control of bots, (oral and gastric stages) Gasterophilus spp | Indication |
| Horses | Treatment and control of Lungworms, Dictyocaulus arnfieldi (adults and fourth-stage larvae) | Indication |
| Horses | Treatment and control of Intestinal Threadworms, Strongyloides westeri (adults) | Indication |
| Horses | Summer sores caused by Habronema | Indication |
| Horses | Summer sores caused by Draschia spp cutaneous third-stage larvae | Indication |
| Horses | Dermatitis caused by neck threadworm microfilariae, Onchocerca sp | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Haemonchus contortus | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, H placei (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Ostertagia circumcincta | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Trichostrongylus axei | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, T colubriformis | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Cooperia oncophora (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, C curticei | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Oesophagostomum columbianum | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, O venulosum (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Nematodirus battus | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, N spathiger | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, S papillosus (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Chabertia ovina (adult only) | Indication |
| Sheep | Treatment and control of the gastrointestinal roundworms, Trichuris ovis (adults only) | Indication |
| Sheep | Treatment and control of the nasal bot, Oestrus ovis | Indication |
| Sheep | Treatment and control of lungworms, D filaria | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Ascaris suum (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Ascarops strongylina (adults) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Hyostrongylus rubidus (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Oesophagostomum species (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of kidneyworms, Stephanurus dentatus (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of lungworms, Metastrongylus species (adults) | Indication |
| Swine | Treatment and control of lice, Haematopinus suis | Indication |
| Swine | Treatment and control of mange mites, Sarcoptes scabiei var suis | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Eqvalan Injection | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec .27% Injection Grower And Feeder Pigs, Ivomec 1% Injection, Ivomec 1% Injection for Cattle And Swine, Ivomec Injection for Cattle | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Liquid | Boehringer lngelheim Animal Health USA Inc. | 1 |
| EQVALAN | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Cattle Paste 0.153% | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard 30, Heartgard Tablets | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Eqvalan Oral Liquid For Horses | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Plus Injection For Cattle | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Ivomec Pour-On | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard Chewables For Dogs | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard Plus | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Ivomec Premix for Swine | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Sustained-Release Bolus for Cattle | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard for Cats | Boehringer lngelheim Animal Health USA Inc. | 1 |
| BMD / Ivomec Premix for Swine | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Acarexx | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Advantage DUO | Elanco US Inc. | 2 |
| ZIMECTERIN Gold Paste | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Equimax | Virbac AH Inc. | 2 |
| Zimecterin-EZ | Farnam Companies Inc. | 1 |
| Iverhart Max | Virbac AH Inc. | 3 |
| Panacur Plus | Intervet Inc. | 3 |
| Duocare | Boehringer lngelheim Animal Health USA Inc. | 2 |
| IVERHART MAX Chew | Virbac AH Inc. | 3 |
| Phoenectin | Elanco US Inc. | 1 |
| Ivermectin Pour-On for Cattle, Phoenectin, Phoenectin, Phoenectin Pour-On for Cattle | Huvepharma EOOD | 1 |
| Phoenectin | Huvepharma EOOD | 1 |
| Iverhart Tablets | Virbac AH Inc. | 1 |
| Noromectin Pour-On for Cattle | Norbrook Laboratories, Ltd. | 1 |
| Phoenectin Paste 1.87% | Elanco US Inc. | 1 |
| Iversol Liquid for Horses | Med-Pharmex Inc. | 1 |
| Ivermectin Chewable Tablets | Cronus Pharma Specialities India Private Limited | 1 |
| Iver-On | Med-Pharmex Inc. | 1 |
| Iverhart Plus Flavored Chewables | Virbac AH Inc. | 2 |
| Bimectin Pour-On | Bimeda Animal Health Limited | 1 |
| Equell | Virbac AH Inc. | 1 |
| Primectin Equine Oral Liquid | First Priority Inc. | 1 |
| Bimectin | Bimeda Animal Health Limited | 1 |
| Privermectin Drench for Sheep | First Priority Inc. | 1 |
| Tri-Heart Plus Chewable Tablets | Heska Corp. | 2 |
| Privermectin | First Priority Inc. | 1 |
| SparMectin-E | Sparhawk Laboratories Inc. | 1 |
| Ecomectin | Huvepharma EOOD | 1 |
| Ivermectin Paste 1.87 % | Med-Pharmex Inc. | 1 |
| Ivermectin Injection | Sparhawk Laboratories Inc. | 1 |
| Normectin Plus | Norbrook Laboratories, Ltd. | 2 |
| Noromectin | Norbrook Laboratories, Ltd. | 1 |
| Bimectin Injection for Cattle and Swine | Bimeda Animal Health Limited | 1 |
| Bimectin Plus | Bimeda Animal Health Limited | 2 |
| SparMectin Plus Clorsulon | Sparhawk Laboratories Inc. | 2 |
| Animec Plus | Chanelle Pharmaceuticals Manufacturing Ltd. | 1 |
| Ivermectin Paste 1.87% | Boehringer lngelheim Animal Health USA Inc. | 1 |
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 7550440 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8080530 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8093219 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8415311 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8470788 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8815816 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 10206939 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9089587 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9233117 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9233118 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9782425 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Multidrug resistance protein 1 | Transporter | IC50 | 7 | WOMBAT-PK | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.41 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.13 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.59 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.24 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.45 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 6.54 | DRUG MATRIX | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | ALLOSTERIC MODULATOR | EC50 | 5.10 | IUPHAR | ||||
| Bile acid receptor | Nuclear hormone receptor | IC50 | 6.59 | CHEMBL | |||||
| Glycine Receptor | Ion channel | AGONIST | EC50 | 6.40 | IUPHAR | ||||
| D(1A) dopamine receptor | GPCR | Ki | 5.65 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.66 | DRUG MATRIX | |||||
| Glutamate-gated chloride channel | Ion channel | MODULATOR | CHEMBL | CHEMBL | |||||
| Glutamate-gated chloride channel | Ion channel | MODULATOR | CHEMBL | CHEMBL | |||||
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Enzyme | IC50 | 5.17 | CHEMBL | |||||
| Sodium/potassium-transporting ATPase subunit alpha-1 | Enzyme | IC50 | 5.08 | CHEMBL | |||||
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Enzyme | IC50 | 4.77 | CHEMBL | |||||
| P2X purinoceptor 4 | Ion channel | ALLOSTERIC MODULATOR | EC50 | 6.60 | IUPHAR |
| ID | Source |
|---|---|
| 4021046 | VUID |
| N0000148510 | NUI |
| D00804 | KEGG_DRUG |
| 4021046 | VANDF |
| C0022322 | UMLSCUI |
| CHEBI:6078 | CHEBI |
| IVM | PDB_CHEM_ID |
| CHEMBL1200633 | ChEMBL_ID |
| D007559 | MESH_DESCRIPTOR_UI |
| DB00602 | DRUGBANK_ID |
| 2373 | IUPHAR_LIGAND_ID |
| 4828 | INN_ID |
| 8883YP2R6D | UNII |
| 6321424 | PUBCHEM_CID |
| 6069 | RXNORM |
| 4941 | MMSL |
| 71965 | MMSL |
| d04101 | MMSL |
| 005266 | NDDF |
| 387559003 | SNOMEDCT_US |
| 96138006 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0032 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0032 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| SOOLANTRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-3823 | CREAM | 10 mg | TOPICAL | NDA | 26 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 0363-4230 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2107 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2107 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4052 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4052 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 11822-4230 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Sklice | HUMAN OTC DRUG LABEL | 1 | 24338-185 | LOTION | 5 mg | TOPICAL | NDA | 16 sections |
| Ivermectin | Human Prescription Drug Label | 1 | 42799-806 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| Ivermectin | Human Prescription Drug Label | 1 | 42799-806 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5587 | TABLET | 3 mg | ORAL | ANDA | 24 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 51316-423 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4211 | LOTION | 5 mg | TOPICAL | ANDA | 27 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 51672-4230 | LOTION | 5 mg | TOPICAL | ANDA | 17 sections |
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-019 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8754 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8754 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-948 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-2242 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| BRIMONIDINE TARTRATE 0.25% / IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 4 | 72934-1028 | GEL | 1 g | TOPICAL | unapproved drug other | 4 sections |
| IVERMECTIN 1% / METRONIDAZOLE 1% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-1130 | GEL | 1 g | TOPICAL | unapproved drug other | 4 sections |
| IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1131 | GEL | 1 g | TOPICAL | unapproved drug other | 4 sections |
| 171083 IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1237 | GEL | 1 g | TOPICAL | unapproved drug other | 4 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76413-155 | TABLET | 3 mg | ORAL | ANDA | 24 sections |